Merrill Lynch Upgrades Amylin Pharmaceuticals (AMLN) to Buy
More News related to AMLN
- Analysts Downgrade Sanofi Aventis Amid Long-Acting Insulin Concerns; Amylin Benefiting (SNY, AMLN, NVO)
- Unusual 11 Mid-Day Movers 6/26: NCS, PALM, SCON, AMLN Higher; DWRI, GRB, BLUD, RBN Lower
- Amylin Pharmaceuticals to Present at Piper Jaffray Europe Conference
- Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009
- Novo Nordisk's (NVO) Victoza Returns More Promising Results Than Lilly's (LLY)/Amylin's (AMLN) Byetta
Merrill Lynch upgrades Amylin Pharmaceuticals (Nasdaq: AMLN) from Neutral to Buy.
Amylin Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of drug candidates for the treatment of diabetes, obesity and other diseases.
Related Categories
UpgradesStocks Mentioned
-0.54Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
